|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
EP0366685B1
(en)
|
1987-06-24 |
1994-10-19 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
|
US5328470A
(en)
|
1989-03-31 |
1994-07-12 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
WO1991006556A1
(en)
|
1989-10-24 |
1991-05-16 |
Gilead Sciences, Inc. |
2' modified oligonucleotides
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
EP0452457B1
(en)
|
1989-11-03 |
1997-08-20 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US5670633A
(en)
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5212295A
(en)
|
1990-01-11 |
1993-05-18 |
Isis Pharmaceuticals |
Monomers for preparation of oligonucleotides having chiral phosphorus linkages
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5506351A
(en)
|
1992-07-23 |
1996-04-09 |
Isis Pharmaceuticals |
Process for the preparation of 2'-O-alkyl guanosine and related compounds
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US6262241B1
(en)
|
1990-08-13 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Compound for detecting and modulating RNA activity and gene expression
|
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
|
CA2027872A1
(en)
|
1990-10-17 |
1992-04-18 |
Jack Sklarchuck |
Method for preparing lead-acid battery plates
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
JP2823959B2
(ja)
|
1991-10-24 |
1998-11-11 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US20030206887A1
(en)
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
NL9201440A
(nl)
|
1992-08-11 |
1994-03-01 |
Univ Leiden |
Triantennaire clusterglycosiden, hun bereiding en toepassing.
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
HU9501974D0
(en)
|
1993-03-31 |
1995-09-28 |
Sterling Winthrop Inc |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
JP3278981B2
(ja)
|
1993-06-23 |
2002-04-30 |
株式会社日立製作所 |
半導体メモリ
|
|
US5571902A
(en)
|
1993-07-29 |
1996-11-05 |
Isis Pharmaceuticals, Inc. |
Synthesis of oligonucleotides
|
|
US5519134A
(en)
|
1994-01-11 |
1996-05-21 |
Isis Pharmaceuticals, Inc. |
Pyrrolidine-containing monomers and oligomers
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5554746A
(en)
|
1994-05-16 |
1996-09-10 |
Isis Pharmaceuticals, Inc. |
Lactam nucleic acids
|
|
US5597909A
(en)
|
1994-08-25 |
1997-01-28 |
Chiron Corporation |
Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
US5856459A
(en)
|
1995-06-06 |
1999-01-05 |
Hybridon, Inc. |
Oligonucleotides specific for hepatitis B virus
|
|
US5985662A
(en)
|
1995-07-13 |
1999-11-16 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of hepatitis B virus replication
|
|
US6127533A
(en)
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
|
US6271358B1
(en)
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
BR9914772A
(pt)
|
1998-10-09 |
2001-12-11 |
Ingene Inc |
Conjunto de elementos genéticos, vetor, célulahospedeira, conjunto para a produção de umasequência de ácido nucléico, método para aprodução in vivo ou in vitro de uma sequência deácido nucléico, transcrição de cdna, molécula deácido nucléico inibidor, transcrição de mrna,molécula heteroduplex e composiçãofarmacêutica
|
|
US5977341A
(en)
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
WO2000053722A2
(en)
|
1999-03-10 |
2000-09-14 |
Phogen Limited |
Delivery of nucleic acids and proteins to cells
|
|
EP1102785B1
(en)
|
1999-06-07 |
2013-02-13 |
Arrowhead Research Corporation |
COMPOSITIONS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
|
|
US7019113B2
(en)
|
1999-06-07 |
2006-03-28 |
Mirus Bio Corporation |
Reversible modification of membrane interaction
|
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
|
US8202979B2
(en)
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
|
CA2442092A1
(en)
|
2001-03-26 |
2002-10-17 |
Ribozyme Pharmaceuticals, Inc. |
Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US20060217331A1
(en)
|
2001-05-18 |
2006-09-28 |
Sirna Therapeutics, Inc. |
Chemically modified double stranded nucleic acid molecules that mediate RNA interference
|
|
EP1627061B1
(en)
|
2001-05-18 |
2009-08-12 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US10590418B2
(en)
|
2001-07-23 |
2020-03-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for RNAi mediated inhibition of gene expression in mammals
|
|
US20030198627A1
(en)
|
2001-09-01 |
2003-10-23 |
Gert-Jan Arts |
siRNA knockout assay method and constructs
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
US6635428B2
(en)
|
2001-12-04 |
2003-10-21 |
Quest Diagnostics Investments Incorporated |
Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
|
|
EP1478656B1
(en)
|
2002-02-01 |
2009-09-16 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
RNA inhibition mediated inhibition of MAP KINASE GENES
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
EP1857547B2
(en)
|
2002-08-05 |
2020-12-02 |
Silence Therapeutics GmbH |
Further novel forms of interfering RNA molecules
|
|
US7923547B2
(en)
|
2002-09-05 |
2011-04-12 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
US7816337B2
(en)
|
2003-02-18 |
2010-10-19 |
Roche Madison Inc. |
Reversible attachment of a membrane active polymer to a polynucleotide
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
CN1257284C
(zh)
|
2003-03-05 |
2006-05-24 |
北京博奥生物芯片有限责任公司 |
一种体外阻断乙肝病毒表达的方法
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
WO2005009346A2
(en)
*
|
2003-06-24 |
2005-02-03 |
Mirus Corporation |
Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
|
|
US20080207539A1
(en)
|
2003-09-01 |
2008-08-28 |
Patrick Arbuthnot |
Self-Processing Rna Expression Cassette
|
|
EP1715896A4
(en)
|
2004-01-12 |
2009-01-07 |
Lorus Therapeutics Inc |
ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST RIBONUCLEOTIDE REDUCTASE R2 AND USE THEREOF IN POLYTHERAPIES FOR THE TREATMENT OF CANCER
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
CA2566286A1
(en)
|
2004-05-11 |
2005-12-08 |
Rnai Co., Ltd. |
Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
|
|
WO2006017932A1
(en)
|
2004-08-18 |
2006-02-23 |
Genesense Technologies Inc. |
Small interfering rna molecules against ribonucleotide reductase and uses thereof
|
|
KR20100060018A
(ko)
|
2005-03-09 |
2010-06-04 |
재단법인 목암생명공학연구소 |
작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
|
|
PL1866414T3
(pl)
|
2005-03-31 |
2012-10-31 |
Calando Pharmaceuticals Inc |
Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
|
|
KR20080036650A
(ko)
|
2005-08-17 |
2008-04-28 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
Ｒｎａ 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자
|
|
CN101426912A
(zh)
|
2005-08-17 |
2009-05-06 |
瑟纳治疗公司 |
介导rna干扰的化学修饰短干扰核酸分子
|
|
RU2418068C2
(ru)
|
2005-08-17 |
2011-05-10 |
Сирна Терапьютикс, Инк. |
Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
|
|
EP2202239A1
(en)
*
|
2005-11-01 |
2010-06-30 |
Alnylam Pharmaceuticals Inc. |
RNAI inhibition of influenza virus replication
|
|
CN101024088A
(zh)
|
2006-02-20 |
2007-08-29 |
桂林医学院 |
抗乙型肝炎病毒微小核糖核酸干扰分子及其设计方法
|
|
CN101500548A
(zh)
|
2006-08-18 |
2009-08-05 |
弗·哈夫曼-拉罗切有限公司 |
用于体内递送多核苷酸的多缀合物
|
|
FR2909555B1
(fr)
|
2006-12-11 |
2009-01-30 |
Oreal |
Emulsion e/h a effet correcteur pour la peau
|
|
US8232257B2
(en)
|
2007-03-27 |
2012-07-31 |
University Of Iowa Research Foundation |
RNA interference mediated inactivation of hepatitis B virus in a subject
|
|
WO2008131419A2
(en)
|
2007-04-23 |
2008-10-30 |
Alnylam Pharmaceuticals, Inc. |
Glycoconjugates of rna interference agents
|
|
CN101755049B
(zh)
|
2007-05-29 |
2014-03-12 |
约翰内斯堡威特沃特斯兰德大学 |
初级微rna表达盒
|
|
US20100209491A1
(en)
|
2007-09-17 |
2010-08-19 |
Mogam Biotechnology Research Institute |
Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv
|
|
WO2009045457A2
(en)
|
2007-10-02 |
2009-04-09 |
Rxi Pharmaceuticals Corp. |
Tripartite rnai constructs
|
|
EP2229186A2
(en)
|
2007-12-04 |
2010-09-22 |
Alnylam Pharmaceuticals Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
US8575123B2
(en)
|
2008-04-11 |
2013-11-05 |
Tekmira Pharmaceuticals Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
CN101322847A
(zh)
|
2008-06-23 |
2008-12-17 |
淮安市第四人民医院 |
基于siRNA池干扰的复合载体介导的抗乙肝病毒基因药物
|
|
KR20110110776A
(ko)
|
2008-12-18 |
2011-10-07 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2010129023A2
(en)
|
2009-04-28 |
2010-11-11 |
President And Fellows Of Harvard College |
Supercharged proteins for cell penetration
|
|
DK2427472T3
(en)
|
2009-05-05 |
2016-09-12 |
Miragen Therapeutics |
Lipophilic polynukleotidkonjugater
|
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
|
US9050375B2
(en)
|
2009-07-06 |
2015-06-09 |
Hoffmann-La Roche, Inc. |
Bi-specific digoxigenin binding antibodies
|
|
US20110152349A1
(en)
|
2009-12-18 |
2011-06-23 |
Anke Geick |
Compositions and methods for inhibiting expression of il-18 genes
|
|
US9198972B2
(en)
|
2010-01-28 |
2015-12-01 |
Alnylam Pharmaceuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
|
PH12012501596A1
(en)
|
2010-02-24 |
2017-02-03 |
Arrowhead Res Corporation |
Compositions for targeted delivery of sirna
|
|
EP2390327A1
(en)
|
2010-05-27 |
2011-11-30 |
Sylentis S.A. |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
RU2745848C2
(ru)
|
2010-08-17 |
2021-04-01 |
Сирна Терапьютикс, Инк. |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
|
US9290760B2
(en)
|
2010-09-15 |
2016-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
CN101948834B
(zh)
|
2010-09-16 |
2012-07-04 |
山东大学 |
用于治疗HBV的siRNA
|
|
ES2730393T3
(es)
|
2010-10-28 |
2019-11-11 |
Benitec Biopharma Ltd |
Tratamiento contra el VHB
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
RU2582235C2
(ru)
|
2010-12-29 |
2016-04-20 |
Ф.Хоффманн-Ля Рош Аг |
Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
|
|
SI3505528T1
(sl)
|
2011-04-21 |
2021-04-30 |
Glaxo Group Limited |
Modulacija izražanja virusa hepatitisa B (HBV)
|
|
PL2709989T3
(pl)
|
2011-05-18 |
2018-06-29 |
Janssen Sciences Ireland Uc |
Pochodne chinazoliny do leczenia infekcji wirusowych i dalszych chorób
|
|
PT2726613T
(pt)
*
|
2011-06-30 |
2018-10-26 |
Arrowhead Pharmaceuticals Inc |
Composições e métodos para inibição da expressão de genes do vírus da hepatite b
|
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
CA2842039A1
(en)
|
2011-08-26 |
2013-03-07 |
Arrowhead Research Corporation |
Poly(vinyl ester) polymers for in vivo nucleic acid delivery
|
|
UA118649C2
(uk)
|
2011-11-18 |
2019-02-25 |
Елнілем Фармасьютікалз, Інк. |
ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
|
|
MX2014001965A
(es)
|
2012-04-18 |
2014-03-31 |
Arrowhead Res Corp |
Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
|
|
WO2013159109A1
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Modulation of hepatitis b virus (hbv) expression
|
|
US9212363B2
(en)
|
2012-05-11 |
2015-12-15 |
City Of Hope |
RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
CN103333890B
(zh)
|
2012-12-21 |
2015-04-15 |
厦门成坤生物技术有限公司 |
治疗乙型病毒性肝炎的rna干扰制剂
|
|
US9943604B2
(en)
|
2013-09-20 |
2018-04-17 |
Ionis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
WO2015050871A2
(en)
|
2013-10-04 |
2015-04-09 |
Novartis Ag |
Organic compounds to treat hepatitis b virus
|
|
EP3137115B1
(en)
|
2014-05-01 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
CN104059916A
(zh)
|
2014-06-17 |
2014-09-24 |
湖北医药学院附属太和医院 |
乙肝病毒特异性的microRNA样siRNA序列及其用途
|
|
TWI864340B
(zh)
|
2014-10-10 |
2024-12-01 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
TWI769565B
(zh)
|
2014-11-10 |
2022-07-01 |
美商阿尼拉製藥公司 |
Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
|
|
EP3253343B1
(en)
*
|
2015-02-06 |
2023-04-19 |
Essity Hygiene and Health Aktiebolag |
Absorbent article
|
|
JP6924744B2
(ja)
|
2015-07-17 |
2021-08-25 |
アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
|
|
US20170137821A1
(en)
|
2015-07-17 |
2017-05-18 |
Arcturus Therapeutics, Inc. |
Molecules and agents for treating hepatitis b virus
|
|
CN108350455A
(zh)
*
|
2015-07-29 |
2018-07-31 |
阿布特斯生物制药公司 |
用于使b型肝炎病毒基因表达沉默的组合物和方法
|
|
CN115957337A
(zh)
|
2015-08-07 |
2023-04-14 |
箭头药业股份有限公司 |
乙型肝炎病毒感染的RNAi疗法
|
|
TWI859114B
(zh)
|
2016-04-11 |
2024-10-21 |
加拿大商艾爾布圖斯生技公司 |
靶向組合物
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
JOP20170056B1
(ar)
|
2016-09-02 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة
|
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
|
EA202091517A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
|
|
TW202415645A
(zh)
|
2018-03-01 |
2024-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
TWI872048B
(zh)
|
2019-02-07 |
2025-02-11 |
美商艾羅海德製藥公司 |
用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑
|
|
US20200332297A1
(en)
|
2019-04-18 |
2020-10-22 |
Janssen Pharmaceuticals, Inc. |
Combination therapy for treating hepatitis b virus infection
|
|
WO2020232024A1
(en)
|
2019-05-13 |
2020-11-19 |
Vir Biotechnology, Inc. |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
|
JP2022536945A
(ja)
|
2019-06-18 |
2022-08-22 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ＨＢＶ）ワクチンおよびＨＢＶを標的化するＲＮＡｉの組合せ
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
TW202245809A
(zh)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
用於治療b型肝炎病毒感染之組合療法
|